Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.38 |
| ▸ | FABP1 | P07148 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | SOD1 | P00441 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6957018 | 0.83 | SLC6A2 (0.53) | ADRA1A | |
| SCHEMBL6962031 | 0.83 | SLC6A2 (0.42) | ADRA1ALRRK2 | |
| SCHEMBL6960596 | 0.82 | SGPL1 (0.43) | ADRA1A | |
| SCHEMBL6962600 | 0.82 | KMT2A (0.44) | CHRNB2CHRNA4ADRA1AFFAR1 | |
| SCHEMBL6963118 | 0.80 | LTA4H (0.46) | ADRA1ALTA4H | |
| SCHEMBL6956969 | 0.78 | CYP2D6 (0.43) | BACE1 | |
| SCHEMBL6966088 | 0.77 | ADRA1A (0.39) | ADRA1A | |
| SCHEMBL6960436 | 0.77 | LMNA (0.40) | ADRA1ALTA4H | |
| Hydrochloric Acid SCHEMBL6968688 | 0.76 | ADRA1A (0.39) | ADRA1ALTA4H | |
| SCHEMBL6954794 | 0.75 | CHRNB2 (0.51) | CHRNB2CHRNA4ADRA1ACHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610721-B2 | Imidazo heterocyclic compounds | NOVO NORDISK A/S (DK) | 2003-08-26 | — | — | US | disclosed |
| EP-1268483-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-20010049385-A1 | Imidazo heterocyclic compounds | HIGH POINT PHARMACEUTICALS, LLC | 2001-12-06 | — | — | US | disclosed |
| WO-2001068651-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049385-A1 | Imidazo heterocyclic compounds | HRH4, HRH3, HRH2 | CHRNB2 436/4885CHRNA4 130/4885ADRA1A 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.